Chronic Lymphocytic Leukemia: Molecular Oncology Tumor Boards

Please note that MOC credit submission for this course is temporarily down. It is our goal to get this resolved very shortly.

This free case-based activity includes a crowd-sourced discussion of a 62-year-old male with past history of hypertension and atrial fibrillation who presents to his primary care physician with complaints of fatigue of 6 months duration. On exam, he is noted to have bilateral cervical and axillary lymphadenopathy, measuring 3 x 2 cm in size. There is no hepatosplenomegaly noted. There is no family history of leukemia/lymphoma.

Laboratory profile shows that the total WBC count is 35 x 109/L, with 98% lymphocytes, HB is 10 gm/dL, and PLT are 90 x 109/L. Serum chemistries are unremarkable.

Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives:
1.    Explain the difference between prognostic and predictive biomarkers in patients with newly diagnosed CLL
2.    Discuss the treatment options for patients with previously untreated standard risk CLL
3.    Identify clonal evolution in patients with previously treated CLL and prescribe appropriate therapy for such patients

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on November 22, 2020. Participants must complete all necessary course components by this date to receive credit